Vestal Point Capital LP Invests $30.40 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Vestal Point Capital LP purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 250,000 shares of the biotechnology company's stock, valued at approximately $30,398,000. Sarepta Therapeutics accounts for 1.8% of Vestal Point Capital LP's holdings, making the stock its 24th largest position. Vestal Point Capital LP owned 0.26% of Sarepta Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Manchester Capital Management LLC increased its position in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after buying an additional 156 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at about $36,000. Steward Partners Investment Advisory LLC increased its position in shares of Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after buying an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 216 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Trading Down 2.3%

Shares of NASDAQ:SRPT traded down $0.89 during trading on Friday, reaching $37.90. 2,048,795 shares of the company traded hands, compared to its average volume of 1,784,357. The firm has a market capitalization of $3.72 billion, a price-to-earnings ratio of 30.32 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 52-week low of $34.10 and a 52-week high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The business's fifty day moving average is $54.60 and its 200-day moving average is $94.62.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. Sarepta Therapeutics's revenue was up 80.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.73 EPS. As a group, analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Guggenheim cut their price objective on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Wells Fargo & Company cut their price objective on Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Evercore ISI lowered Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price objective for the company. in a report on Thursday, May 8th. Oppenheimer cut their price objective on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Finally, Piper Sandler cut their price objective on Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $122.61.

Insider Activity at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.